[Korea Biomedical Review] Can Korea make a global blockbuster drug?

[Korea Biomedical Review] Can Korea make a global blockbuster drug?

Can Korea make a global blockbuster drug? The government is supporting the pharmaceutical industry’s efforts. In 2020, the government announced a national strategy to innovate the bio-health industry and designated the pharmaceutical and biopharma sector one of the three largest industries to lead the economic growth in the future, along with future-oriented vehicles and system semiconductors. This policy direction is likely to continue even after the presidential election on March 9, 2022. How ...

#PA #PublicAffairs #마콜컨설팅그룹 #이보형사장 #퍼블릭어페어즈

원문링크 : [Korea Biomedical Review] Can Korea make a global blockbuster drug?

 등록된 다른 글

[Korea Times] How Candlelight protests Impact Business Environment

[매경럭스맨 칼럼] 퍼블릭 어페어즈(PA) 역량 강화로 규제환경 정책 리스크 대응해야 - 마콜컨설팅그룹 사장 이보형

[매경춘추] 통해야 오래간다 - 마콜컨설팅그룹 사장 이보형

[매경춘추] 결심과 지속가능성 - 마콜컨설팅그룹 사장 이보형

[Korea Biomedical Review] [Column] How should Korea set health insurance reimbursements?

[매경럭스맨 칼럼] 시장 위의 “보이는 손(Visible hand)”과 경영전략 - 마콜컨설팅그룹 사장 이보형

[Korea Biomedical Review] Conflicts between doctors, nurses over Nursing Act legislation

[Korea Biomedical Review] Korea should curb health-harming behaviors to improve health finance